Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
Konstantinidou M., Zarganes‐Tzitzikas T., Magiera‐Mularz K., Holak TA., Dömling A.
AbstractThe PD‐1/PD‐L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD‐1 and PD‐L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.